News from cell therapeutics inc

May 30, 2014, 01:30 ET
CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.

 Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing...

May 29, 2014, 01:30 ET

Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare...

Apr 29, 2014, 16:01 ET

Cell Therapeutics Reports First Quarter 2014 Financial Results

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014. "In the first...

Apr 29, 2014, 01:30 ET

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for...

Apr 22, 2014, 01:30 ET

Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday,...

Mar 05, 2014, 01:30 ET

Cell Therapeutics to Present at the 26th Annual ROTH Conference

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual...

Mar 04, 2014, 16:00 ET

Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013....

Mar 03, 2014, 01:30 ET

CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will...

Feb 27, 2014, 01:30 ET

NICE Publishes Final Guidance on PIXUVRI® (pixantrone)

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the...

Feb 25, 2014, 01:30 ET

Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2013 financial...

Feb 03, 2014, 01:30 ET

Cell Therapeutics Appoints Karen Ignagni to Board of Directors

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective...

Jan 30, 2014, 01:30 ET

CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of...

Jan 28, 2014, 01:30 ET

Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has...

Jan 14, 2014, 01:30 ET

Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress...

Jan 13, 2014, 01:30 ET

Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two...

Jan 06, 2014, 01:30 ET

PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from NICE

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the...

Jan 02, 2014, 01:30 ET

Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S. Food and Drug Administration...

Dec 18, 2013, 01:30 ET

Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that CTI has received the remaining $5 million from Hercules Technology Growth...

Dec 10, 2013, 01:30 ET

Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical...

Dec 09, 2013, 11:30 ET

Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting

 Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from an integrated analysis of data from two completed Phase 2...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer